Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

Following its initial approval at 150 mg, trastuzumab-strf has also been approved at 420 mg for the treatment of several HER2 ...

The DESTINY-Breast12 trial revealed that trastuzumab deruxtecan (T-DXd) effectively targets brain metastases in HER2-positive ...

Trastuzumab deruxtecan has shown efficacy in patients with metastatic breast cancer with low expression of human epidermal growth factor receptor 2 (HER2) after previous chemotherapy. We conducted ...

Adjuvant trastuzumab reveals associations with improved disease-free survival in 1-year vs 9-week administration of the drug ...

Celltrion announced that its Brazilian subsidiary won the Federal Government of Brazil’s bid to supply HERZUMA (trastuzumab-pkrb) for the fifth consecutive year, with around 660,000 vials to be ...

Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase I for Metastatic Breast Cancer.

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Combining endocrine therapy with the dual HER2 blockade of trastuzumab and pertuzumab and the CDK4/6 inhibitor ribociclib ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial ...